Midi Health Prescription and Intake Process: What to Expect Step by Step

How the Midi Health Intake Works

The intake begins with a digital questionnaire that collects symptom severity, menstrual history, surgical history, current medications, family history of breast cancer or cardiovascular disease, and mental health screening data. This pre-visit form typically takes 10 to 15 minutes to complete. The platform uses the collected data to match patients with a clinician who has specific training in menopause medicine.

Before the video visit, Midi may ask patients to upload recent lab results or order new bloodwork. The 2022 Endocrine Society clinical practice guideline on hormone therapy recommends baseline evaluation of cardiovascular risk factors and breast cancer history before initiating menopausal hormone therapy (1). Midi's intake mirrors this recommendation by flagging contraindications before the clinician encounter. Patients with a history of estrogen-receptor-positive breast cancer, active liver disease, or unexplained vaginal bleeding are identified during this screening step, which aligns with FDA labeling for conjugated estrogens and estradiol products (2).

The structured pre-screening is one reason the platform can deliver a treatment plan in a single visit. Clinicians arrive at the consultation already aware of the patient's risk profile.

What Happens During the Video Visit

The first consultation runs 30 to 60 minutes. This is longer than the average primary care visit for menopause complaints, which a 2019 survey in the journal Menopause found lasted a median of 5 minutes when menopause was not the primary reason for the appointment (3). Midi's visit structure creates time for a detailed symptom inventory.

During the visit, the clinician walks through the Menopause Rating Scale (MRS) or a comparable validated instrument to quantify symptom burden across three domains: somatic, psychological, and urogenital. The clinician also reviews lab values (FSH, estradiol, TSH, lipid panel, and metabolic panel are commonly ordered), discusses treatment goals, and explains the risk-benefit profile of each option.

A prescribing decision usually happens in real time. Patients leave the visit with either an electronic prescription sent to their preferred pharmacy or a plan for additional workup. The 2017 North American Menopause Society (NAMS) position statement recommends individualized therapy using the lowest effective dose for the shortest duration consistent with treatment goals (4). Midi clinicians cite this framework explicitly during visits, according to patient-reported accounts on review platforms.

Prescription Options Available Through Midi

Midi clinicians prescribe across a broad formulary. The hormone therapy options include transdermal estradiol patches (doses ranging from 0.025 mg to 0.1 mg per day), oral estradiol (0.5 mg to 2 mg), topical estradiol gel, vaginal estrogen (cream, tablet, or ring), and oral or vaginal micronized progesterone (100 mg to 200 mg for endometrial protection in patients with a uterus).

The REPLENISH trial (N=1,835) demonstrated that the combination of conjugated estrogens and bazedoxifene (Duavee) reduced hot flash frequency by 74% versus 51% for placebo at 12 weeks (5). Some Midi clinicians prescribe this combination for patients who prefer to avoid progestins.

Non-hormonal alternatives are also part of the prescribing toolkit. Fezolinetant (Veozah), approved by the FDA in May 2023, reduced moderate-to-severe vasomotor symptoms by roughly 60% in the SKYLIGHT 1 trial (N=501) at 12 weeks compared to 43% with placebo (6). For patients with contraindications to estrogen, this represents a meaningful option. Low-dose paroxetine (Brisdelle, 7.5 mg), the only FDA-approved SSRI for hot flashes, is another frequently prescribed alternative. Gabapentin at 300 mg to 900 mg daily is used off-label for vasomotor symptoms and co-occurring sleep disruption.

Testosterone therapy for low libido, while not FDA-approved for women in the United States, is prescribed off-label by some Midi clinicians based on the 2019 global consensus statement on testosterone therapy for women, which found moderate-quality evidence supporting a dose of 5 mg daily transdermal testosterone for hypoactive sexual desire disorder in postmenopausal women (7).

Is Midi Health Legit? Evaluating the Clinical Model

Midi Health operates as a legitimate telehealth medical practice with licensed clinicians in each state where it provides services. The platform requires its providers to hold active, unrestricted medical licenses and, according to its public materials, prioritizes candidates with menopause-specific training or NAMS certification.

This matters because menopause education in U.S. medical training remains limited. A 2023 survey published in Menopause found that only 31.3% of OB/GYN residency programs offered a formal menopause medicine curriculum (8). The gap between clinical need and provider readiness is a core problem Midi aims to solve.

The platform's legitimacy is also supported by its insurance partnerships. Midi accepts coverage from several major carriers, including Aetna, UnitedHealthcare, and Cigna in select states. Insurance credentialing requires verification of provider licenses, malpractice coverage, and clinical qualifications. The credentialing process itself functions as an external quality check.

One limitation to note: Midi does not perform physical examinations. The 2022 U.S. Preventive Services Task Force (USPSTF) recommendation against routine hormone therapy for chronic disease prevention in postmenopausal women was based partly on trials that included in-person assessments (9). Whether a video-only model captures the same clinical nuance is an open question. For straightforward vasomotor symptoms in otherwise healthy women aged 45 to 60, the evidence supports telehealth-initiated HRT as clinically reasonable. Complex cases (prior VTE, undiagnosed bleeding, family BRCA status) may warrant in-person evaluation.

Midi Health Cost and Insurance

The cost structure has two tiers. Patients with accepted insurance pay standard copays and coinsurance for specialist visits. Cash-pay patients can expect to pay approximately $250 to $350 for the initial visit and $150 to $250 for follow-up visits, though pricing varies by state and provider.

These figures place Midi in the mid-range of telehealth menopause platforms. Some competitors charge monthly membership fees ($50 to $199 per month) that include unlimited messaging and a set number of visits. Midi's fee-for-service model means patients pay per encounter but avoid ongoing subscription charges during periods when they do not need active clinical adjustments.

Medication costs are separate. Generic transdermal estradiol patches run $20 to $60 per month at most pharmacies with a GoodRx coupon. Branded products like Divigel (estradiol gel) or Veozah (fezolinetant) can exceed $500 per month without insurance. The AACE 2017 guidelines on menopause management note that cost is a significant factor in treatment adherence and recommend that clinicians discuss formulary status and out-of-pocket burden during prescribing decisions (10).

Midi clinicians can send prescriptions to any U.S. pharmacy, including mail-order services, which gives patients flexibility to price-shop.

Midi Health vs. Alternatives

Several telehealth platforms compete in the menopause space. Alloy Health, Evernow, and Gennev (now part of the Unified Women's Healthcare network) each offer online HRT prescribing. The differences lie in clinical model, insurance acceptance, and prescribing philosophy.

Alloy Health uses an asynchronous intake followed by a provider review, meaning some patients receive prescriptions without a live video visit. This model is faster but offers less opportunity for shared decision-making. A 2021 systematic review in BMJ Open found that synchronous telehealth consultations produced higher patient satisfaction scores than asynchronous models for chronic condition management (pooled OR 1.64 to 95% CI 1.22, 2.19) (11).

Evernow also uses a largely asynchronous model with optional video visits. Its formulary is narrower, focusing primarily on estradiol and progesterone, with fewer non-hormonal options readily available compared to Midi.

Gennev historically emphasized health coaching alongside clinical care. Following its acquisition, the platform has shifted toward a more traditional telehealth model. Coaching can be valuable for lifestyle modifications (the Women's Health Initiative Dietary Modification Trial showed that dietary intervention reduced self-reported vasomotor symptoms by 14.7% over one year (12)), but it does not replace pharmacologic management for moderate-to-severe symptoms.

Midi's differentiator is the live-visit-first model combined with insurance billing. For patients who want a real-time clinical conversation and prefer not to pay entirely out of pocket, this combination is uncommon in the menopause telehealth market.

Follow-Up Care and Ongoing Management

After the initial visit, Midi schedules follow-ups at intervals that match the treatment plan. Patients starting hormone therapy typically have a check-in at 6 to 8 weeks to assess symptom response, side effects, and dose adjustments. The NAMS 2022 practice pearl on HRT follow-up recommends reassessment within 3 months of initiation, including evaluation of bleeding patterns for patients on combined estrogen-progestogen therapy (13).

Between visits, Midi provides asynchronous messaging with the care team. Prescription refills can be handled through this channel without a full visit, reducing friction for patients on stable regimens. This hybrid model (synchronous visits for clinical decisions, asynchronous messaging for maintenance) aligns with the chronic disease management model described in the AHA 2020 telehealth scientific statement (14).

Annual reassessment is standard. The clinician reviews the ongoing risk-benefit balance of hormone therapy, orders updated labs, and adjusts the plan as the patient's hormonal status evolves through the menopause transition. For patients on systemic estrogen, the USPSTF recommends breast cancer screening with mammography every two years for women aged 50 to 74 (15), and Midi clinicians coordinate these referrals with local imaging centers.

Limitations of the Midi Health Model

No telehealth platform is appropriate for every patient. Women with complex medical histories (prior stroke, active coronary artery disease, known thrombophilia) may need in-person evaluation before starting or adjusting hormone therapy. The 2017 Hormone Therapy Position Statement from NAMS explicitly notes that the decision to use HRT should incorporate individual risk assessment that may include imaging or specialty consultation (4).

Midi does not prescribe compounded bioidentical hormones. The FDA and the Endocrine Society have both stated that compounded hormones lack the standardized safety and efficacy data required for FDA-approved products (16). While some patients specifically seek compounded formulations, Midi's decision to avoid them reflects a conservative, evidence-based prescribing philosophy.

Geographic availability is another constraint. Midi operates in 30+ states, but patients in states without coverage must use a competitor or seek local care.

The initial visit cost without insurance exceeds what some patients can afford. For uninsured or underinsured women, community health centers and academic menopause clinics may provide more affordable access to the same FDA-approved therapies, typically at sliding-scale pricing.

Patients considering Midi should confirm their insurance is accepted in their state, prepare recent lab results to maximize the first visit's efficiency, and arrive with a written list of symptoms ranked by severity. The NAMS menopause symptom checklist, available free at menopause.org, is a useful tool to structure that preparation.